Diabetes News

 2017-11-29
Qvin’s Q-Pad™ Earns Special Mention in TIME’s Best Inventions 2024

Qvin’s Q-Pad™ Earns Special Mention in TIME’s Best Inventions 2024


Qvin's Q-Pad™ recognized in TIME's 'Best Inventions 2024' for Advancing Women's HealthMORE
Beta Bionics Launches iLet Bionic Pancreas with Abbott FreeStyle Libre 3 Plus Sensor

Beta Bionics Launches iLet Bionic Pancreas with Abbott FreeStyle Libre 3 Plus Sensor


Beta Bionics launches iLet Bionic Pancreas with FreeStyle Libre 3 Plus, offering real-time, autonomous glucose monitoring for type 1 diabetes users.MORE
FTC Sues Major Pharmacy Benefit Managers for Inflating Insulin Prices

FTC Sues Major Pharmacy Benefit Managers for Inflating Insulin Prices


The lawsuit targets Optum Rx, Caremark, and Express Scripts, accusing them of unfair practices that raise insulin costs, while the companies deny wrongdoingMORE
Tandem t:X2 Insulin Pump Now Compatible with Lyumjev in EU

Tandem t:X2 Insulin Pump Now Compatible with Lyumjev in EU


Enhances flexibility and quality of life for diabetes patientsMORE
Dexcom CGM Worn in Space for the First Time!

Dexcom CGM Worn in Space for the First Time!


Astronauts are taking their diabetes tech to new heights—literally! For the first time ever, the Dexcom G6 Continuous Glucose Monitoring (CGM) system is being worn in space as part of the Polaris Da...MORE
FDA Approves Embecta's New Insulin-Delivery System for Both Type 1 and Type 2 Diabetes

FDA Approves Embecta’s New Insulin-Delivery System for Both Type 1 and Type 2 Diabetes


In a significant development for diabetes care, Embecta Corp. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its groundbreaking disposable insulin-delivery system, ...MORE
Medtronic Announces FDA Approval of Simplera™ CGM and Global Partnership with Abbott

Medtronic Announces FDA Approval of Simplera™ CGM and Global Partnership with Abbott


The Simplera™ continuous glucose monitor (CGM) was approved by the Food and Drug Administration (FDA) on August 7, 2024. According to a press release from Medtronic, Simplera™ is Medtronic’s fir...MORE
Is the Rising Use of Cannabis Among U.S. Adults with Diabetes a Health Concern?

Is the Rising Use of Cannabis Among U.S. Adults with Diabetes a Health Concern?


According to a recent study published in the July 22, 2024 issue of Diabetes Care, the percentage of adult Americans with diabetes who use cannabis increased by 33.7% between 2021 and 2022. The findin...MORE
Diamyd Medical's Vaccine Gets FDA Fast Track

Diamyd’s Type 1 Diabetes Prevention Therapy Gets FDA Fast Track


Diamyd Medical is making waves with its innovative therapy, Diamyd, designed to prevent type 1 diabetes. Recently, the U.S. Food and Drug Administration (FDA) granted Diamyd its second Fast Track desi...MORE

Abbott Gets FDA Clearance for Two Over-the-Counter CGMs


Abbott Laboratories announced on June 10, 2024 that two new over-the-counter (OTC) continuous glucose monitoring (CGM) devices had received FDA clearance. These two devices—one aimed at health-consc...MORE
Dexcom Launches the G7 with Apple Watch Integration

Dexcom Launches the G7 with Apple Watch Integration


On June 5, 2024, Dexcom announced that its G7 continuous glucose monitor (CGM) now connects directly to the Apple Watch in the U.S. Dexcom first revealed this implementation in March. With its officia...MORE
The Price of Uncertainty: Unveiling the Impact of Unexpected Type 1 Diabetes Diagnoses

The Price of Uncertainty: Unveiling the Impact of Unexpected Type 1 Diabetes Diagnoses


Sanofi commissioned a study to determine the impact of an unexpected type 1 diabetes diagnosis. Learn all about what they discovered.MORE
JDRF Rebrands as Breakthrough T1D to Accelerate Type 1 Research and Advocacy

JDRF Rebrands as Breakthrough T1D to Accelerate Type 1 Research and Advocacy


On June 4, 2024, the Juvenile Diabetes Research Foundation (JDRF) announced that Breakthrough T1D was the new name for the organization. During the organization’s annual Government Day meeting i...MORE
FDA Approves CamAPS FX Hybrid Closed-Loop Insulin Delivery App

FDA Approves CamAPS FX Hybrid Closed-Loop Insulin Delivery App


The US Food and Drug Administration (FDA) has approved a hybrid, closed-loop, insulin-delivery Android app. On May 29, 2024, CamDiab, a company that creates state-of-the-art diabetes management techno...MORE
Tandem Mobi Pump and the Dexcom G7 CGM Are Now Connected

Tandem Mobi Pump and the Dexcom G7 CGM Are Now Connected


On May 29, 2024, Tandem Diabetes Care and Dexcom, Inc. announced that the Dexcom G7 continuous glucose monitor (CGM) and the Tandem Mobi insulin pump are now completely compatible. Tandem Mobi connect...MORE
Novo’s Once-Weekly Insulin a No-Go with FDA Advisory Panel

Novo’s Once-Weekly Insulin Is a No-Go with FDA Advisory Panel


Advisers to the U.S. Food and Drug Administration (FDA) voted 7–4 not to approve Novo Nordisk’s once-weekly, experimental insulin known as Awiqli, citing a lack of benefit over risk. The FDA h...MORE
Sequel’s twiist Automated Insulin Delivery System Receives FDA Clearance

The twiist Automated Insulin Delivery System Receives FDA Clearance


On March 18, 2024, Sequel Med Tech announced that its partner—DEKA Research & Development Corp.—received FDA clearance for the twiist Automated Insulin Delivery (AID) system. Using the FDA-cle...MORE
Dexcom Introduces Direct-to-Apple-Watch Feature for its G7 CGM

Dexcom Introduces Direct-to-Apple-Watch Feature for its G7 CGM


Dexcom recently introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. This means G7 will be the only CGM system that can connect directly to Apple Watch without...MORE
Payment Assistance and Savings Program Extended for the Eversense E3 CGM

Payment Assistance and Savings Program Extended for the Eversense E3 CGM


Ascensia Diabetes Care and Senseonics have extended their Eversense Payment Assistance and Simple Savings (PASS) program—aimed to help people in the U.S. more affordably access the Eversense E3 cont...MORE
The Tandem Mobi is Now Available

The Tandem Mobi is Now Available


World’s Smallest Automated Insulin Delivery System Lets People With Diabetes Experience the Benefits of Control-IQ TechnologyMORE
t:slim X2 Becomes First Automated-Insulin-Delivery System to Fully Integrate With the FreeStyle Libre 2 Plus CGM

t:slim X2 Becomes First Automated-Insulin-Delivery System to Fully Integrate With the FreeStyle Libre 2 Plus CGM


t:slim X2 becomes first automated-insulin-delivery system to fully integrate with the FreeStyle Libre 2 Plus continuous glucose monitoring system MORE

ADA Standards of Care 2024: So What’s New?


Diabetes research, technology, and treatments are rapidly changing. Here's what you need to know about the 2024 Standards of Care.MORE

Dexcom G7 Now Integrated with T:slim X2


Tandem’s T:slim X2 insulin pump is the first automated insulin delivery system to fully integrate with Dexcom’s G7 continuous glucose monitoring system.MORE

Benefits of Using a Dexcom G7 CGM During Pregnancy


Managing diabetes during pregnancy can be tough, but Dexcom Chief Operating Officer Jake Leach shares how a CGM can help.MORE

GoodRx Announces New Way for People to Access Lantus for $35


GoodRx partnered with Sanofi to offer $35 insulin coupons to all, regardless of their insurance status, for use at pharmacies nationwide. MORE

New Program Recognizes Leaders In Diabetes Care


Received stellar diabetes care? Encourage your providers to apply to be recognized as leaders in diabetes care.MORE

Vertex VX-880 Clinical Results Lead To Insulin-Independence


Here's what you need to know about Vertex's recent results from their stem-cell therapy for type 1 diabetes.MORE

Ketogenic Diet for Kids with Diabetes Carries Risk


The American Academy of Pediatrics warns against a ketogenic diet, a popular low-carbohydrate diet, for children with diabetes.MORE

Dexcom ONE Now Available in France


Dexcom ONE, a continuous glucose monitoring (CGM) system, is now available for people with diabetes in France.MORE

Beyond Type 2 Expands to Provide Resources to Canada


Canadians can now share their stories, get connected to the community and find critical resources on all things type 2 diabetes. MORE

How You Can Try a Dexcom CGM for Free


Learn why continuous glucose monitors (CGMs) are beneficial and how you can try the free 10-day Dexcom trial program.MORE

T1D Clinical Trial Search Engine Now Available In Spanish


Beyond Type 1 collaborates with Antidote Technologies and JDRF to launch the first-ever Spanish-language clinical trial search engine for type 1 diabetes.MORE

Project IMPACT: Bringing CGM Access to a Pharmacy Near You


Interview with Robert E. Nichols, PharmD, BCPS, Clinical Pharmacist, who is participating in the pilot program for better CGM access. MORE

Beyond Type Run Marathon Team Reaches New Milestones in 2023


Beyond Type Run, the stereotype-smashing team of runners proves anybody living with diabetes can go the distance despite their diagnosis.MORE

Moms’ Night Out Aims to Support Caregivers of People with Type 1 Diabetes


“Moms’ Night Out” expands after exciting launch. Attend an upcoming event for mothers of children with diabetes in these three cities!MORE

JDRF’s Children’s Congress: Finding A Cure For Type 1 Diabetes


Learn more about JDRF, its mission behind the biannual Children’s Congress and the impact of this year's event.MORE

Tandem’s Mobi Approved by the FDA


Tandem’s newest insulin pump, Mobi, was approved by the FDA for people with diabetes age six and up. Here's what you need to know!MORE

A Year in Review: Advancements in Diabetes Tech + Research


This session reviewed the advances and discoveries in research and technology for people living with diabetes over the past year.MORE

Senseonics + UnitedHealthcare Expanding CGM Access


Senseonics announced that UnitedHealthCare will now cover their Eversense E3 implantable CGM, starting July 1, 2023.MORE
Medtronic 780G Receives FDA Approval

Medtronic’s MiniMed 780G Receives FDA Approval 


The FDA has approved Medtronic’s MiniMed 780G, the newest automated insulin dosing (AID) system on the market. MORE
Baqsimi acquired

Eli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes


Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.MORE

Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Affordable


Mark Cuban's Cost Plus Drugs Company just announced that they offer Janssen's Invokana, Invokamet and Invokamet XR for type 2 diabetes.MORE

Why Diabetes Should be Screened by Age Instead of Weight


Many cases of diabetes may be missed by screening only by weight instead of age, especially for some racial and ethnic groups.MORE
Civica

California Partners with Civica Rx to Make More Affordable Insulin 


California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.MORE

Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35


Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024. MORE

Novo Nordisk to Slash Insulin Prices by over 65%


Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.MORE
Freestyle Libre 2 and Freestyle Libre 3 to Integrate with Automated Insulin Delivery Systems

Freestyle Libre 2 and Freestyle Libre 3 to Integrate with Automated Insulin Delivery Systems


Abbott, makers of the Freestyle Libre 2 and 3, modified their sensors to enable integration with automated insulin delivery systems. Here’s what you should know!MORE

$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions


On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.MORE

This New App is Designed to Make Tracking Your Insulin Easier


If you use Lilly brand insulin, this new connected platform is designed to make tracking your diabetes data a lot easier. MORE

Say Hello to BeyondType2.org in French, German and Italian!


BeyondType2.org now offers critical resources in five languages for people living with and impacted by type 2 diabetes.MORE
ADA2022

Diabetes + Dementia: Using Nasal Insulin to Improve Brain Function


With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE
ADA2022

Women + Exercise: It’s Complicated


Women living with type 1 diabetes are told exercise will help better manage their diabetes. That’s easier said than done. MORE
ADA2022

Reaching Everyone — Health Disparities in Physical Activity


People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MORE
ADA2022

Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care


Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE
ADA2022

Race, Racism, and Diabetes Research


Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MORE
ADA2022

Research: Practical Use of Closed-Loop Insulin Pumps


Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MORE
ADA2022

Access to Insulin: In the United States


Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MORE
ADA2022

Access to Insulin: In Low-Income Countries


In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE
tirzepatide weight loss research

Promising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity


The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MORE

Stem Cell Therapy for Type 1 Diabetes: Patient Achieved Insulin Independence on Day 270


A patient in the Vertex Pharmaceutical’s clinical trial using stem-cell therapy to treat type 1 diabetes has achieved insulin independence on Day 270 of the trial. MORE
insulin copays

The Affordable Insulin Now Act: A Step Toward Federal Legislation


The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE

FreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE


Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORE
Dexcom Breakthrough Device Designation

COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings


The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MORE
Eversense E3

Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time


The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MORE

Omnipod 5 Receives FDA Approval


Omnipod 5, a closed-loop tubeless insulin pump with smartphone control that integrates with the Dexcom G6 continuous glucose monitor, has now received FDA approval.MORE
Drug Pricing Investigation

Inside the Drug Pricing Investigation from the House Oversight and Reform Committee


The results of the most recent report from the committee make things clear for the United States — the need for access to affordable healthcare is direr than ever.MORE

The Potential Impact of Build Back Better on American Healthcare


Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MORE
Mark Cuban Pharmacy

Mark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs


Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MORE

A Win for T1D in California: Senate Bill 97 Signed Into Law


The bill requires type 1 diabetes informational materials to be developed for the parents and guardians of pupils in California schools.MORE

Beyond Type 1 Launches Web Platform in Arabic 


Diabetes information, stories, and news are now available in Arabic at ar.beyondtype1.org.MORE

COVID-19 Vaccines For Kids Ages 5 to 11 With Diabetes: What to Know


COVID-19 vaccines are now available for kids age 5+! Learn about safety and managing side effects for kids with type 1 diabetes.MORE
vertex pharmaceuticals stem cell therapy for type 1 diabetes

Stem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%


The early results of a clinical trial using stem-cell therapy to treat type 1 diabetes reduced the patient’s insulin needs by 91%.MORE

Lilly Announces Lower List price for Insulin Lispro


The company will lower the list price of the generic version of Humalog in the U.S. by an additional 40 percent starting January 1, 2022.MORE

Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit


Lilly announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MORE
Latinx Diabetes Initiative

The Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes


Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MORE
Yarishdy Mora

Yarishdy Mora Is Empowering Youth Through Diabetes Education In Mexico


Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MORE
Screened for Type 2 Diabetes

Overweight Adults to Now Be Screened for Type 2 Diabetes At 35


The U.S. Preventive Services Task Force now recommends overweight and obese adults to get screened for Type 2 diabetes at the age of 35.MORE
Freestyle Libre 2

Abbott’s FreeStyle Libre 2 App Receives FDA Clearance


On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MORE
Culturally Sensitive LGBTQ+ Diabetes Health Care

Providing Culturally Sensitive LGBTQ+ Diabetes Health Care


Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MORE
Black Mother With Type 1 Diabetes

High Risk Pregnancy – Mitigating Risks for Type 1 Diabetes + Black Maternal Health Outcomes


Ariel Lawrence, a diabetes advocate and Black mother with type 1 diabetes, shares how she navigated her pregnancy. MORE
disparities in pediatric diabetes

Addressing Disparities in Pediatric Diabetes Treatment In Philadelphia


Terri Lipman shares how incorporating community health workers can tackle disparities in pediatric diabetes treatment. MORE
teplizumab

FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D


The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE

Combating Diabetes Disparities Among The Hispanic Population


At ADA 2021, David Marrero discusses how culturally tailored care can combat diabetes disparities among the Hispanic population.MORE
walmart

Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog


ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MORE
depression among african american

Preliminary Findings On Depression Among African American and Latino Parents of Children With T1D


Samantha Carreon shares preliminary data on the TEAM study which found higher rates of depression among African American and Latino parents.MORE
JP Qualters

Making Broadway More Accessible With JP Qualters


JP Qualters shares his experience on Broadway as a person living with type 1 diabetes and his aspirations for the theater industry.MORE
Zegalogue®

Zegalogue® Is Now Commercially Available In The United States


Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MORE
continuous glucose monitor coverage

Medicare Loosens Restrictions on Continuous Glucose Monitor Coverage


Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORE
vaccine access

COVID-19 Vaccines And Diabetes: Vaccine Access Issues For People Of Color


Communities of color with diabetes face a myriad of barriers when it comes to vaccine access. Experts share how the U.S. can achieve vaccine equity.MORE
diabetes program accessibility

Michelle L. Litchman Focuses On Diabetes Program Accessibility For People Who Are Deaf


Michelle L. Litchman was named a Betty Irene Moore Nurse Fellow. She will focus on diabetes program accessibility for people who are deaf.MORE

Test Strip Subscription Guide


We compiled a rundown of popular companies that offer test strip subscription services and researched each of them to give you some important info.MORE
omnipod 5

Omnipod 5 Pivotal Trial Data Published


Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MORE
ATTD 2021

Breaking News From ATTD 2021


This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORE
mental health

Survey Finds the Pandemic Increased Mental Health Concerns Among People With Diabetes


Cecelia Health conducted a survey that revealed increased mental health concerns among people with diabetes during the COVID-19 pandemic. MORE
bullying

Combating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace


Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MORE
Bigfoot Unity

Bigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA


Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MORE

Asian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research


Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MORE
ramadan

Type 1 Diabetes + Ramadan: Here’s How a Few People Are Observing


People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MORE

The PROTECT Study 


The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE